PMID- 28758949
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2079-4983 (Print)
IS  - 2079-4983 (Electronic)
IS  - 2079-4983 (Linking)
VI  - 8
IP  - 3
DP  - 2017 Jul 30
TI  - Potential New Non-Invasive Therapy Using Artificial Oxygen Carriers for 
      Pre-Eclampsia.
LID - 10.3390/jfb8030032 [doi]
LID - 32
AB  - The molecular mechanisms of pre-eclampsia are being increasingly clarified in 
      animals and humans. With the uncovering of these mechanisms, preventive therapy 
      strategies using chronic infusion of adrenomedullin, vascular endothelial growth 
      factor-121 (VEGF-121), losartan, and sildenafil have been proposed to block 
      narrow spiral artery formation in the placenta by suppressing related possible 
      factors for pre-eclampsia. However, although such preventive treatments have been 
      partly successful, they have failed in ameliorating fetal growth restriction and 
      carry the risk of possible side-effects of drugs on pregnant mothers. In this 
      study, we attempted to develop a new symptomatic treatment for pre-eclampsia by 
      directly rescuing placental ischemia with artificial oxygen carriers (hemoglobin 
      vesicles: HbV) since previous data indicate that placental ischemia/hypoxia may 
      alone be sufficient to lead to pre-eclampsia through up-regulation of sFlt-1, one 
      of the main candidate molecules for the cause of pre-eclampsia. Using a rat 
      model, the present study demonstrated that a simple treatment using hemoglobin 
      vesicles for placental ischemia rescues placental and fetal hypoxia, leading to 
      appropriate fetal growth. The present study is the first to demonstrate 
      hemoglobin vesicles successfully decreasing maternal plasma levels of sFlt-1 and 
      ameliorating fetal growth restriction in the pre-eclampsia rat model (p < 0.05, 
      one-way ANOVA). In future, chronic infusion of hemoglobin vesicles could be a 
      potential effective and noninvasive therapy for delaying or even alleviating the 
      need for Caesarean sections in pre-eclampsia.
FAU - Ohta, Hidenobu
AU  - Ohta H
AD  - Department of Psychophysiology, National Institute of Mental Health, National 
      Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8553, Japan. 
      hideohta@ncnp.go.jp.
AD  - Department of Psychiatry, Asai Hospital, Togane, Chiba 283-0042, Japan. 
      hideohta@ncnp.go.jp.
FAU - Kaga, Maiko
AU  - Kaga M
AD  - Department of Pediatrics, National Hospital Organization Sendai Medical Center, 
      Miyagino-Ku, Sendai, Miyagi 983-0045, Japan. maikokaga@med.tohoku.ac.jp.
FAU - Li, Heng
AU  - Li H
AD  - Department of Mental Retardation and Birth Defect Research, National Institute of 
      Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 
      187-8553, Japan. yinzhidr@ncnp.go.jp.
FAU - Sakai, Hiromi
AU  - Sakai H
AD  - Department of Chemistry, Faculty of Medicine, School of Medicine, Nara Medical 
      University, Kashihara, Nara 634-8521, Japan. hirosakai@naramed-u.ac.jp.
FAU - Okamura, Kunihiro
AU  - Okamura K
AD  - Tohoku Kosai Hospital, Aoba-ku, Sendai, Miyagi 980-0803, Japan. 
      okamura@tohokukosai.com.
AD  - Department of Obstetrics and Gynecology, Tohoku University Hospital, Aoba-ku, 
      Sendai, Miyagi 980-8574, Japan. okamura@tohokukosai.com.
FAU - Yaegashi, Nobuo
AU  - Yaegashi N
AD  - Department of Obstetrics and Gynecology, Tohoku University Hospital, Aoba-ku, 
      Sendai, Miyagi 980-8574, Japan. yaegashi@med.tohoku.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170730
PL  - Switzerland
TA  - J Funct Biomater
JT  - Journal of functional biomaterials
JID - 101570734
PMC - PMC5618283
OTO - NOTNLM
OT  - Keywords: pre-eclampsia
OT  - brain damage
OT  - fetus
OT  - hemoglobin vesicle
OT  - hypoxic condition
OT  - placenta
COIS- The authors declare no conflict of interest
EDAT- 2017/08/02 06:00
MHDA- 2017/08/02 06:01
PMCR- 2017/09/01
CRDT- 2017/08/01 06:00
PHST- 2017/06/26 00:00 [received]
PHST- 2017/07/16 00:00 [revised]
PHST- 2017/07/18 00:00 [accepted]
PHST- 2017/08/01 06:00 [entrez]
PHST- 2017/08/02 06:00 [pubmed]
PHST- 2017/08/02 06:01 [medline]
PHST- 2017/09/01 00:00 [pmc-release]
AID - jfb8030032 [pii]
AID - jfb-08-00032 [pii]
AID - 10.3390/jfb8030032 [doi]
PST - epublish
SO  - J Funct Biomater. 2017 Jul 30;8(3):32. doi: 10.3390/jfb8030032.